Holistic Understanding of the Role of Carbohydrate Antigen 19-9 in Pancreatic Cancer Screening, Early Diagnosis, and Prognosis: A Systematic Review.

Autor:	Janga LSN; Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Sambe HG; Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Yasir M; Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Man RK; Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Gogikar A; Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Nanda A; Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Mohammed L; Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2023 Aug 30; Vol. 15 (8), pp. e44382. Date of Electronic Publication: 2023 Aug 30 (Print Publication: 2023).
DOI:	10.7759/cureus.44382
Abstrakt:	Pancreatic ductal adenocarcinoma (PDAC) is a significant challenge due to its silent progression and well-advanced, unresectable, complicated presentation. Detecting this disease early on is crucial, and researchers have been investigating various potential biological markers, such as carbohydrate antigen 19-9 (CA 19-9), hoping to find indicators that can aid in its early detection. The primary focus of this review is on the diagnostic usefulness of CA 19-9 in detecting pancreatic cancer (PC) in the beginning stage and its usefulness in predicting progression. The database search of articles from PubMed, PMC, the Cochrane Library, and Google Scholar identified 227 articles published from 2013 to 2023. The keyword mix used in the search technique included terms like "CA 19-9," "pancreatic cancer," "diagnosis," and "early detection." This study provides evidence of CA 19-9's ability in detecting PDAC in the pre-diagnostic stage. But since the outcomes were inconsistent among the included trials, further analysis is required to develop standardized diagnostic criteria and methodologies. Furthermore, because of the variability of the study, it is not easy to make firm conclusions on CA 19-9's sensitivity as well as specificity in the first stage of pancreatic neoplasm. This in-depth overview of the available literature provides new insights into using CA 19-9 as a biological marker for detecting undiagnosed PC before progressing into the advanced stage, and was proven beneficial. However, this has to be shown in broader research with adequate sample size. Although it shows promise as a diagnostic tool, further study is required to confirm these findings. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Janga et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu